McDonald's fourth-quarter comparable sales top estimates

Investing.com
10 Feb

Investing.com - McDonald’s Corporation (NYSE:MCD) comparable sales topped average analyst estimates in the fourth quarter, as the burger giant's international licensed markets business was boosted by strength in the Middle East and Japan.

In the three months ended on December 31, global comparable sales expanded by 0.4%, decelerating from 3.4% in the year-ago period, as the business was hit by weaker demand in the U.S.

But the uptick was better than analysts' expectations for a decline of 0.93%, Bloomberg consensus forecasts showed.

Same-store sales at its international developmental licensed markets climbed by 4.1%, surpassing growth of 0.7% a year ago and projections for a drop of 0.38%. Performance at the segment was led by the Middle East and Japan, McDonald's noted.

In a statement, CEO Chris Kempczinski said the business, which has recently joined other fast-food chains in offering more lower-priced options to attract consumers, is focused on providing "outstanding value" and "exciting menu innovation."

McDonald's has been pushing to address a dent to guest count and sales sparked by an E. coli outbreak last year that infected dozens of people and killed at least one person, according to the Centers for Disease Control and Prevention (CDC).

Kempczinski has apologized for the outbreak, adding that he was "confident" in the safety of the group's food. Executives have also said they are moving to "restor[e] consumer confidence" and get its U.S. business back to showing "strong momentum."

Group-wide, revenue for the fourth quarter slipped by 0.3% year-on-year to $6.39 billion, compared with expectations of $6.45 billion. Operating income edged up by 2.4% to $2.87 billion.

For the full year, operating profit increased by 1% to $11.71 billion despite McDonald's booking a pre-tax expense of $221 million related to restructuring charges.

Shares in McDonald's rose by more than 1% in premarket U.S. trading on Monday.

Related Articles

McDonald's fourth-quarter comparable sales top estimates

Pliant Therapeutics stock plummets after trial pause

ON Semiconductor stock tumbles as Q4 earnings miss, guidance disappoints

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10